biological tumor markers

Summary

Summary: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.

Top Publications

  1. ncbi Apoptosis and cell-cycle regulatory proteins in colorectal carcinoma: relationship to tumour stage and patient survival
    M A Elkablawy
    Quantitative Biomarkers Group, Department of Pathology, Cancer Research Centre, Queen's University of Belfast, Grosvenor Road, Belfast BT12 6BL, UK
    J Pathol 194:436-43. 2001
  2. ncbi Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer
    Junjie Peng
    Department of Abdominal Surgery, Cancer Hospital of Fudan University, Shanghai Medical College, Fudan University, Shanghai, China
    Cancer J 14:54-61. 2008
  3. ncbi Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets
    Claus Lindbjerg Andersen
    Molecular Diagnostic Laboratory, Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, DK-8200 Aarhus N, Denmark
    Cancer Res 64:5245-50. 2004
  4. ncbi Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells
    Michael F Clarke
    Stanford University School of Medicine, Stanford, California, USA
    Cancer Res 66:9339-44. 2006
  5. ncbi Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    D J Slamon
    Department of Medicine, U C L A School of Medicine 90024
    Science 244:707-12. 1989
  6. ncbi Triple-negative breast cancer: clinical features and patterns of recurrence
    Rebecca Dent
    Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
    Clin Cancer Res 13:4429-34. 2007
  7. ncbi Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
    Torsten O Nielsen
    Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 10:5367-74. 2004
  8. ncbi Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma
    Danit Lebanony
    Rosetta Genomics Ltd, 10 Plaut St, Rehovot 76706, Israel
    J Clin Oncol 27:2030-7. 2009
  9. ncbi Unique microRNA molecular profiles in lung cancer diagnosis and prognosis
    Nozomu Yanaihara
    Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Cell 9:189-98. 2006
  10. ncbi A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004

Research Grants

  1. Early Biomarkers of Lung cancer by Gene Array Analysis
    Susan Boggs; Fiscal Year: 2003
  2. Protein Biomarkers of Cancer Risk in Older Persons
    Christopher Li; Fiscal Year: 2007
  3. Phase II Study of 44Gy from 131I-81C6 for CNS Tumors
    David Reardon; Fiscal Year: 2004
  4. P21 INDUCTION BY BRCA2
    Fergus Couch; Fiscal Year: 2002
  5. Molecular signatures of HNSCC in response to targeted therapies
    Christine Chung; Fiscal Year: 2009
  6. Molecular signatures of HNSCC in response to targeted therapies
    Christine Chung; Fiscal Year: 2007
  7. Methodology of Phase I and II trials of anticancer CAM
    Andrew Vickers; Fiscal Year: 2004
  8. CLINICAL RESEARCH CURRICULUM
    David Ransohoff; Fiscal Year: 2004
  9. BRCA2 missense mutations and breast cancer
    Fergus Couch; Fiscal Year: 2009
  10. BRCA2 missense mutations and breast cancer
    Fergus Couch; Fiscal Year: 2007

Detail Information

Publications226 found, 100 shown here

  1. ncbi Apoptosis and cell-cycle regulatory proteins in colorectal carcinoma: relationship to tumour stage and patient survival
    M A Elkablawy
    Quantitative Biomarkers Group, Department of Pathology, Cancer Research Centre, Queen's University of Belfast, Grosvenor Road, Belfast BT12 6BL, UK
    J Pathol 194:436-43. 2001
    ..In conclusion, bcl-2 immunoreactivity was associated with apoptosis and could be used in combination with Dukes' stage as a means of predicting prognosis in colorectal cancer...
  2. ncbi Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer
    Junjie Peng
    Department of Abdominal Surgery, Cancer Hospital of Fudan University, Shanghai Medical College, Fudan University, Shanghai, China
    Cancer J 14:54-61. 2008
    ..The purpose of this study was to investigate the significance of CD44 variant 6 (CD44v6) in predicting the treatment outcome of locally advanced adenocarcinoma of the rectum after total mesorectal excision (TME)...
  3. ncbi Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets
    Claus Lindbjerg Andersen
    Molecular Diagnostic Laboratory, Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, DK-8200 Aarhus N, Denmark
    Cancer Res 64:5245-50. 2004
    ..The presented strategy can be applied to evaluate the suitability of any normalization gene candidate in any kind of experimental design and should allow more reliable normalization of RT-PCR data...
  4. ncbi Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells
    Michael F Clarke
    Stanford University School of Medicine, Stanford, California, USA
    Cancer Res 66:9339-44. 2006
  5. ncbi Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    D J Slamon
    Department of Medicine, U C L A School of Medicine 90024
    Science 244:707-12. 1989
    ..The data presented further support the concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers...
  6. ncbi Triple-negative breast cancer: clinical features and patterns of recurrence
    Rebecca Dent
    Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
    Clin Cancer Res 13:4429-34. 2007
    ..To compare the clinical features, natural history, and outcomes for women with "triple-negative" breast cancer with women with other types of breast cancer...
  7. ncbi Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
    Torsten O Nielsen
    Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 10:5367-74. 2004
    ..These studies show that many basal-like tumors express HER1, which suggests candidate drugs for evaluation in these patients...
  8. ncbi Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma
    Danit Lebanony
    Rosetta Genomics Ltd, 10 Plaut St, Rehovot 76706, Israel
    J Clin Oncol 27:2030-7. 2009
    ..In this study, we set out to identify specific microRNA biomarkers for the identification of squamous cell carcinoma, and to use such markers for the development of a standardized assay...
  9. ncbi Unique microRNA molecular profiles in lung cancer diagnosis and prognosis
    Nozomu Yanaihara
    Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Cell 9:189-98. 2006
    ..These results indicate that miRNA expression profiles are diagnostic and prognostic markers of lung cancer...
  10. ncbi A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004
    ..The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures...
  11. ncbi Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
    Marc Tischkowitz
    Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada
    BMC Cancer 7:134. 2007
    ..The IHC pattern that best defines basal-like tumors is under investigation and various combinations of ER, PR, HER2-, CK5/6+ and EGFR+ have been tested...
  12. ncbi Enabling personalized cancer medicine through analysis of gene-expression patterns
    Laura J Van't Veer
    Agendia BV, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    Nature 452:564-70. 2008
    ..In particular, tests that predict the clinical outcome for patients on the basis of the genes expressed by their tumours are likely to increasingly affect patient management, heralding a new era of personalized medicine...
  13. ncbi The Ki-67 protein: from the known and the unknown
    T Scholzen
    Division of Molecular Immunology, Research Center Borstel, Germany
    J Cell Physiol 182:311-22. 2000
    ..There are indications, however, that Ki-67 protein expression is an absolute requirement for progression through the cell-division cycle...
  14. ncbi Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics
    Bryan T Hennessy
    Department of Gynecologic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 69:4116-24. 2009
    ..PIK3CA mutations, EMT, and stem cell-like characteristics likely contribute to the poor outcomes of MBC and suggest novel therapeutic targets...
  15. ncbi The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation
    Tiffany M Phillips
    Department of Radiation Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095-1714, USA
    J Natl Cancer Inst 98:1777-85. 2006
    ..These findings offer a possible mechanism for the accelerated repopulation of tumor cells observed during gaps in radiotherapy...
  16. ncbi Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis
    Karen H Lu
    Ovarian Cancer Research Laboratory, Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:3291-300. 2004
    ..CONCLUSIONS: Our data are consistent with the possibility that a limited number of markers in combination might identify >99% of epithelial ovarian cancers despite the heterogeneity of the disease...
  17. ncbi Assessment of a HER2 scoring system for gastric cancer: results from a validation study
    M Hofmann
    Institute of Pathology, Klinikum Kassel, Kassel, Germany
    Histopathology 52:797-805. 2008
    ..The aim was to establish a HER2 scoring system for gastric cancer to identify suitable patients for enrollment in a trial of trastuzumab (Herceptin) in advanced metastatic gastric cancer...
  18. ncbi Cell surface tumor endothelial markers are conserved in mice and humans
    E B Carson-Walter
    The Howard Hughes Medical Institute, Baltimore, Maryland 21231, USA
    Cancer Res 61:6649-55. 2001
    ..The coordinate expression of TEM1, TEM5, and TEM8 on tumor endothelium in humans and mice makes these genes attractive targets for the development of antiangiogenic therapies...
  19. ncbi MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma
    Aaron J Schetter
    Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    JAMA 299:425-36. 2008
    ..MicroRNAs have potential as diagnostic biomarkers and therapeutic targets in cancer. No study has evaluated the association between microRNA expression patterns and colon cancer prognosis or therapeutic outcome...
  20. ncbi Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, British Columbia, Canada
    Clin Cancer Res 14:1368-76. 2008
    ..This study directly compares the prognostic significance between three- and five-biomarker surrogate panels to define intrinsic breast cancer subtypes, using a large clinically annotated series of breast tumors...
  21. ncbi HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
    C Gravalos
    Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain
    Ann Oncol 19:1523-9. 2008
    ..This review summarizes the rationale, preclinical evidence, retrospective clinical analyses, and the interim clinical data pertaining HER2 therapies in gastric cancer...
  22. ncbi Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer
    Gennadi V Glinsky
    Sidney Kimmel Cancer Center, San Diego, California 92121, USA
    J Clin Invest 115:1503-21. 2005
    ....
  23. ncbi Development of personalized tumor biomarkers using massively parallel sequencing
    Rebecca J Leary
    Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Sci Transl Med 2:20ra14. 2010
    ..This approach provides an exquisitely sensitive and broadly applicable approach for the development of personalized biomarkers to enhance the clinical management of cancer patients...
  24. ncbi Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus
    Francine Walker
    Department of Pathology, Institut de la Santé et de la Recherche Médicale Unité773, Hopital Bichat Claude Bernard, 75018 Paris, France
    Hum Pathol 40:1517-27. 2009
    ..The finding that EGFR, c-Met, and VEGFR1 involved in carcinogenesis are well-represented and coexpressed in anal cancers, especially in HIV-positive population, suggests possible novel targeted treatments for anal diseases...
  25. ncbi High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer
    Johan Staaf
    Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, Lund, Sweden
    Breast Cancer Res 12:R25. 2010
    ....
  26. ncbi Symbiotic bacteria direct expression of an intestinal bactericidal lectin
    Heather L Cash
    Center for Immunology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    Science 313:1126-30. 2006
    ..We propose that these proteins represent an evolutionarily primitive form of lectin-mediated innate immunity, and that they reveal intestinal strategies for maintaining symbiotic host-microbial relationships...
  27. ncbi Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53
    S W Beenken
    Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Ann Surg 233:630-8. 2001
    ..To assess the prognostic significance of molecular biomarkers, particularly c-erbB-2 and p53, through study of prospective clinical data and archival breast cancer tissues for women accrued to the Alabama Breast Cancer Project...
  28. ncbi CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity
    Shengyong Yin
    Department of General Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, People s Republic of China
    Int J Cancer 120:1444-50. 2007
    ..The implication that CD133 might be one of the markers for HCC cancer stem-like cells needed further investigation...
  29. ncbi Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer
    Ying Xie
    Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA
    Lung Cancer 67:170-6. 2010
    ..82% sensitivity and 100.00% specificity by sputum cytology. The measurement of altered miRNA expression in sputum could be a useful noninvasive approach for the diagnosis of lung cancer...
  30. ncbi Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
    Bas Kreike
    Division of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 9:R65. 2007
    ..We examined the histopathological and gene-expression profile of triple-negative tumors to define subgroups with specific characteristics, including risk of developing distant metastases...
  31. ncbi Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design
    Margaret S Pepe
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 100:1432-8. 2008
    ..Common biases that pervade the biomarker research literature would be eliminated if these rigorous standards were followed...
  32. ncbi FOXA1 expression in breast cancer--correlation with luminal subtype A and survival
    Sunil Badve
    Department of Pathology, Indiana University School of Medicine, Indianapolis, USA
    Clin Cancer Res 13:4415-21. 2007
    ..It segregates with genes that characterize the luminal subtypes in DNA microarray analyses. The utility of FOXA1 as a possible independent prognostic factor has not been determined in breast cancers...
  33. ncbi Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas
    Keith Hoek
    Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, 15 York Street, New Haven, CT 06520-8059, USA
    Cancer Res 64:5270-82. 2004
    ..These results provide a comprehensive view of changes in advanced melanoma relative to normal melanocytes and reveal new targets that can be used in assessing prognosis, staging, and therapy of melanoma patients...
  34. ncbi Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer
    Michail Ignatiadis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Clin Cancer Res 14:2593-600. 2008
    ..To investigate the prognostic value of the molecular detection of circulating tumor cells (CTCs) using three markers [cytokeratin 19 (CK19), mammaglobin A (MGB1), and HER2] in early breast cancer...
  35. ncbi Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer
    Peng Lee
    Department of Pathology, New York University Medical Center, New York, NY 10003, USA
    Gynecol Oncol 96:671-7. 2005
    ..0001) in univariate and multivariate analyses. CONCLUSIONS: The PR is an independent marker, with its overexpression associated with a favorable prognosis in women with ovarian cancer...
  36. ncbi Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer
    Alex Soltermann
    Institute for Surgical Pathology, Department of Pathology, University Hospital Zurich, Zurich, Switzerland
    Clin Cancer Res 14:7430-7. 2008
    ....
  37. ncbi Basal carcinoma of the breast revisited: an old entity with new interpretations
    E Korsching
    Institute of Pathology, University of Muenster, Germany
    J Clin Pathol 61:553-60. 2008
    ..Clinical consequences and potential future research directions driven by the definition of basal breast cancers will also be discussed...
  38. ncbi Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues
    Junming Guo
    Ningbo University School of Medicine, Ningbo 315211, Zhejiang Province, China
    J Gastroenterol Hepatol 24:652-7. 2009
    ..MicroRNAs (miRNAs) play important roles in carcinogenesis. The global miRNA expression profile of gastric cancer has not been reported. The purpose of the present study was to determine the miRNA expression profile of gastric cancer...
  39. ncbi Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays
    Anders Carlsson
    Department of Immunotechnology, Lund University, BMC D13, SE 221 84 Lund, Sweden
    Eur J Cancer 44:472-80. 2008
    ..In a longer perspective, antibody microarray analysis could provide a tool for the development of improved diagnostics and intensified biomarker discovery for breast cancer patients...
  40. ncbi The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass
    Richard G Moore
    Women and Infants Hospital, Brown University, Providence, RI 02925, USA
    Gynecol Oncol 108:402-8. 2008
    ..Because elevated CA125 levels occur in many benign gynecologic conditions, we set out to identify other novel biomarkers that would increase the sensitivity and specificity of CA125...
  41. ncbi A novel five-antibody immunohistochemical test for subclassification of lung carcinoma
    Brian Z Ring
    Department of Research and Development, Applied Genomics Inc, Burlingame, CA 94010, USA
    Mod Pathol 22:1032-43. 2009
    ..The results also suggest that if validated in prospectively defined clinical trials this classifier might identify candidates for targeted therapy that are overlooked with current diagnostic approaches...
  42. ncbi Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck
    Pernille Lassen
    Department of Experimental Clinical Oncology, Aarhus University Hospital, Noerrebrogade 44, DK 8000 Aarhus C, Denmark
    J Clin Oncol 27:1992-8. 2009
    ....
  43. ncbi Periostin is frequently overexpressed and enhances invasion and angiogenesis in oral cancer
    B S M S Siriwardena
    Department of Oral Maxillofacial Pathobiology, Division of Frontier Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, 1 2 3 Kasumi, Hiroshima, Japan
    Br J Cancer 95:1396-403. 2006
    ..In summary, these findings suggest that Periostin may promote invasion and angiogenesis in OSCC, and that Periostin can be a strong marker for prediction of metastasis in oral cancer patients...
  44. ncbi Integrative approach for differentially overexpressed genes in gastric cancer by combining large-scale gene expression profiling and network analysis
    A Takeno
    Department of Surgery, Graduate School of Medicine, Osaka University, 2 2 Yamadaoka Suita, Osaka 565 0871, Japan
    Br J Cancer 99:1307-15. 2008
    ..This integrated approach could help to identify candidate players in gastric carcinogenesis and progression. These genes are potential markers of gastric cancer regardless of stage...
  45. ncbi Application of mesothelin immunostaining in tumor diagnosis
    Nelson G Ordonez
    University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 27:1418-28. 2003
    ..Finally, the strong mesothelin reactivity seen in the adenomatoid tumors (3 of 3) provides further support for a mesothelial derivation for this lesion...
  46. ncbi Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery
    Julio E Celis
    Danish Centre for Translational Breast Cancer Research, and Department of Proteomics in Cancer, Institute of Cancer Biology, The Danish Cancer Society, DK 2100 Copenhagen, Denmark
    Mol Cell Proteomics 3:327-44. 2004
    ....
  47. ncbi A review and update on cholangiocarcinoma
    Matthew J Olnes
    Department of Internal Medicine, Johns Hopkins Bayview Medical Center and Johns Hopkins School of Medicine, Baltimore, MD, USA
    Oncology 66:167-79. 2004
    ..Particular focus is on recent studies into the cellular and molecular pathogenesis of the disease, recent chemotherapy trials, and newer methods of staging and screening for this devastating malignancy...
  48. ncbi Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer
    K S Goonetilleke
    Department of Surgery, Hepatobiliary Surgical Unit, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK
    Eur J Surg Oncol 33:266-70. 2007
    ..This systematic review examines studies using biochemical markers for the diagnosis of pancreatic cancer in order to appraise their role in contemporary management algorithms...
  49. ncbi Mesothelin-family proteins and diagnosis of mesothelioma
    Bruce W S Robinson
    University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, Western Australia, Perth, Australia
    Lancet 362:1612-6. 2003
    ..Identification of such a marker would be useful in diagnosis of mesothelioma and for monitoring responses to treatment and screening at-risk individuals...
  50. ncbi The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis
    A P Meert
    Dept of Internal Medicine, Jules Bordet Institute, Brussels, Belgium
    Eur Respir J 20:975-81. 2002
    ..Epidermal growth factor receptor might be a poor prognostic factor for survival in nonsmall-cell lung cancer. The amplitude of the impact is small, however, and may be subject to publication bias...
  51. ncbi Plastins: versatile modulators of actin organization in (patho)physiological cellular processes
    Veerle Delanote
    Department of Medical Protein Research, Flanders Interuniversity Institute for Biotechnology (VIB, Ghent University, Faculty of Medicine and Health Sciences, Albert Baertsoenkaai 3, B-9000 Ghent, Belgium
    Acta Pharmacol Sin 26:769-79. 2005
    ..T-plastin, on the other hand, is possibly involved in DNA repair. Finally, both T- and L-plastin are implicated in several diseases, and L-plastin is considered to be a valuable marker for cancer...
  52. ncbi Regulation of ovarian function: the role of anti-Müllerian hormone
    Alexandra L L Durlinger
    Department of Internal Medicine, Erasmus MC, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Reproduction 124:601-9. 2002
    ....
  53. ncbi Reporting recommendations for tumor marker prognostic studies (REMARK)
    Lisa M McShane
    Biometric Research Branch, National Cancer Institute, Executive Plaza North, 6130 Executive Blvd, Bethesda, MD 20892 7434, USA
    J Natl Cancer Inst 97:1180-4. 2005
    ....
  54. ncbi Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma
    Mariana Capurro
    Division of Molecualr and Cell Biology, Sunnybrook and Women's College Health Sciences Center and Deaprtment of Medical Biophysics, University of Toronto, Ontario, Canada
    Gastroenterology 125:89-97. 2003
    ..The simultaneous determination of GPC3 and AFP may significantly increase the sensitivity for diagnosis of HCC...
  55. ncbi Periostin: novel diagnostic and therapeutic target for cancer
    Y Kudo
    Department of Oral and Maxillofacial Pathobiology, Division of Frontier Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
    Histol Histopathol 22:1167-74. 2007
    ..This review summarizes the recent understanding of Periostin roles in tumor development and speculates on the usefulness of Periostin as a therapeutic and diagnostic target for cancer...
  56. ncbi HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas
    M F Press
    Norris Comprehensive Cancer Center and Department of Pathology, University of Southern California School of Medicine, Los Angeles, CA 90033, USA
    J Clin Oncol 15:2894-904. 1997
    ....
  57. ncbi Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection
    Shawn A Ritchie
    Phenomenome Discoveries Inc, Saskatoon, SK, Canada
    BMC Med 8:13. 2010
    ..Using tandem-mass spectrometry (MS/MS) high throughput MS technology we evaluated the utility of selected markers and this technology for discriminating between CRC and healthy subjects...
  58. ncbi Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes
    Emad A Rakha
    Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham University, Nottingham, United Kingdom
    Clin Cancer Res 15:2302-10. 2009
    ..It is widely perceived that BLBC and TN tumors are synonymous and BLBC can be defined using a TN definition without the need for the expression of basal markers...
  59. ncbi Ovarian carcinoma subtypes are different diseases: implications for biomarker studies
    Martin Köbel
    Department of Pathology, Genetic Pathology Evaluation Centre of the Prostate Research Centre, Vancouver General Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    PLoS Med 5:e232. 2008
    ..We examined variation in biomarker expression rates between subtypes, and how this influences correlations between biomarker expression and stage at diagnosis or prognosis...
  60. ncbi Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA
    Katrin Panzitt
    Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, A 8036 Graz, Austria
    Gastroenterology 132:330-42. 2007
    ..We searched the human genome for novel genes including ncRNAs related to hepatocellular carcinoma (HCC)...
  61. ncbi Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome
    Richard W Tothill
    Peter MacCallum Cancer Center, University of Melbourne, Melbourne, Australia
    Clin Cancer Res 14:5198-208. 2008
    ..The study aim to identify novel molecular subtypes of ovarian cancer by gene expression profiling with linkage to clinical and pathologic features...
  62. ncbi MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status
    Tone F Bathen
    Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, 7489 Trondheim, Norway
    Breast Cancer Res Treat 104:181-9. 2007
    ..MR-determined metabolic phenotype may have a future role as a supplement for clinical decision-making-concerning adjuvant treatment and the adaptation to more individualised treatment protocols...
  63. ncbi Transcriptome profile of human colorectal adenomas
    Jacob Sabates Bellver
    Institute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland
    Mol Cancer Res 5:1263-75. 2007
    ....
  64. ncbi Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma
    M J Wallard
    Department of Oncology, Hutchison MRC Research Centre, University of Cambridge, Hills Road, Cambridge CB2 2XZ, UK
    Br J Cancer 94:569-77. 2006
    ..This work forms the basis for further functional studies, which will help to confirm the MMPs as potential diagnostic and therapeutic targets in early bladder cancer...
  65. ncbi Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer
    Nuran Bektas
    Institute of Pathology, University Hospital of the RWTH Aachen, Aachen, Germany
    BMC Cancer 8:42. 2008
    ....
  66. ncbi Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome
    Kim L Wang
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 109:658-67. 2007
    ..It is not known whether EGFR plays a similar role in esophageal and EGJ adenocarcinomas...
  67. ncbi E2F-1 overexpression correlates with decreased proliferation and better prognosis in adenocarcinomas of Barrett oesophagus
    K Evangelou
    Molecular Carcinogenesis Group, Department of Histology and Embryology, School of Medicine, University of Athens, Greece
    J Clin Pathol 61:601-5. 2008
    ..To date there are no data regarding E2F-1 expression and its relationship with tumour kinetics (proliferation, apoptosis) in adenocarcinomas that develop on Barrett oesophagus...
  68. ncbi Survivin expression is associated with bladder cancer presence, stage, progression, and mortality
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, Texas 75390 9110, USA
    Cancer 109:1106-13. 2007
    ....
  69. ncbi Osteopontin-c is a selective marker of breast cancer
    Mana Mirza
    College of Pharmacy, University of Cincinnati Medical Center, Cincinnati, OH 45267, USA
    Int J Cancer 122:889-97. 2008
    ..In conjunction, osteopontin-c, ER and HER2 reliably predict grade 2-3 breast cancer. Hence, osteopontin-c is a diagnostic and prognostic marker that may have value in a diagnostic panel together with conventional breast cancer markers...
  70. ncbi Study of HER2/neu status in Qatari women with breast carcinoma
    Kakil I Rasul
    Department of Medicine Hematology Oncology Section, PO Box 3050, Doha, Qatar
    Saudi Med J 24:832-6. 2003
    ..The study is aimed at determining the prevalence of HER2/neu overexpression in Qatari women with breast cancer and to assess the survival in patients with HER2/neu positive tumors...
  71. ncbi C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer
    Angela F Logullo
    Departamento de Patologia da Universidade Federal de São Paulo, Sao Paulo, Brazil
    Oncol Rep 18:121-6. 2007
    ....
  72. ncbi Prostanoid receptor EP1 expression in breast cancer
    Mangesh A Thorat
    Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Mod Pathol 21:15-21. 2008
    ..059). Expression of EP1 is frequently seen in human breast cancers. Nuclear expression of EP1 correlates with good prognosis markers like node negative status and PR expression...
  73. ncbi Lack of correlation between expression of human mammaglobin mRNA in peripheral blood and known prognostic factors for breast cancer patients
    Yung Chang Lin
    Division of Hematology Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, 199 Tung Hwa North Road, Taipei 105, Taiwan
    Cancer Sci 94:99-102. 2003
    ..Further evaluation of hMAM mRNA in combination with other molecular markers to follow post-operative breast cancer patient is warranted...
  74. ncbi Down-regulation of fragile histidine triad expression in prostate carcinoma
    Rebecca L Fouts
    Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Cancer 97:1447-52. 2003
    ..Numerous studies have indicated that the FHIT gene on chromosome 3p may play an important role in human neoplasia, although very few studies have investigated the FHIT gene in prostate carcinoma...
  75. ncbi The prognostic significance of CD44s and CD44v6 expression in stage two breast carcinoma: an immunohistochemical study
    S F Morris
    National Breast Cancer Research Institute (NBCRI, University College Hospital, Galway, Ireland
    Eur J Surg Oncol 27:527-31. 2001
    ..The increased expression of variant CD44 isoforms seen in breast neoplasia may merely be a marker for loss of control of alternative splicing within tumour tissue...
  76. ncbi Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma
    E Bollito
    Dipartimento di Anatomia Patologica, , Orbassano, Italy
    Ann Oncol 12:S159-64. 2001
    ..03) particularly in metastatic cases. CONCLUSIONS: These data support the concept that NE differentiation in human prostate cancer has a negative prognostic significance. Circulating CgA levels reflect immunohistochemical findings...
  77. ncbi Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer
    J Horiguchi
    Second Department of Surgery, Gunma University Faculty of Medicine, Showa machi 3 39 15, Maebashi, Gunma 371 8511, Japan
    Br J Cancer 86:222-5. 2002
    ..In conclusion, dihydropyrimidine dehydrogenase is a possible prognostic factor in patients with breast cancer treated with 5-fluorouracil or 5-fluorouracil derivatives...
  78. ncbi Expression of cyclin D1 and Ki-67 in squamous cell carcinoma of the oral cavity: clinicopathological and prognostic significance
    Juan Carlos de Vicente
    Department of Oral and Maxillofacial Surgery, University Hospital of Oviedo, Oviedo, Spain
    Oral Oncol 38:301-8. 2002
    ..Cyclin D1 and Ki-67 overexpression were positively correlated...
  79. ncbi The significance of monoamine oxidase-A expression in high grade prostate cancer
    Donna M Peehl
    Department of Urology, Stanford University School of Medicine, Stanford, California, USA
    J Urol 180:2206-11. 2008
    ..We investigated whether monoamine oxidase-A expression correlates with another basal cell protein, CD44, in high grade cancer and whether either is associated with an aggressive phenotype...
  80. ncbi Loss of 14-3-3 sigma protein expression and presence of human papillomavirus type 16 E6 in oral squamous cell carcinoma
    Ujjal K Bhawal
    BDS, Department of Diagnostic Science, Division of Pathology and High Tech Research Center, Kanagawa Dental College, Yokosuka 238 8580, Japan
    Arch Otolaryngol Head Neck Surg 134:1055-9. 2008
    ..14-3-3 Sigma is an exclusive epithelial marker, and data on its expression in different malignancies are very scarce...
  81. ncbi CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation
    C Jones
    The Ludwig Institute for Cancer Research UCL Breast Molecular Pathology Group, Royal Free and University College Medical School, UK
    Br J Cancer 85:422-7. 2001
    ..Therefore it appears that grade III invasive ductal carcinomas contain a subset of tumours with specific morphological and cytogenetic characteristics, and probably prognosis for the patient...
  82. ncbi Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma
    Akikazu Kawase
    Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Int J Cancer 123:1053-9. 2008
    ..092). The results of this study highlight the importance of podoplanin expression by CAFs and provide new insights into the biology of the cancer microenvironment in adenocarcinoma of the lung...
  83. ncbi Immunohistochemical evaluation is not prognostic for recurrence in fully staged high-risk endometrial cancer
    J Fanning
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Richard D Ruppert Health Center, Medical College of Ohio, 3120 Glendale Avenue, Toledo, OH 43614 5809, USA
    Int J Gynecol Cancer 12:286-9. 2002
    ..19-.96). Only stage and grade were predictive of tumor recurrence (P = 0.04,.02). We conclude that in completely staged high risk endometrial cancer, commonly used immunohistochemical risk factors are not predictive for recurrence...
  84. ncbi Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung
    Mizuki Ikehara
    Department of Thoracic Oncology, Kanagawa Cancer Center, Asahi-ku, Yokohama 241-0815, Japan
    Oncol Rep 9:835-8. 2002
    ..014; Wilcoxon test, p=0.021). It can be concluded that the expression of survivin in tumor cells is a factor of poor prognosis in patients with small adenocarcinoma of the lung...
  85. ncbi Association between multidrug resistance-associated protein 1 and poor prognosis in patients with nasopharyngeal carcinoma treated with radiotherapy and concurrent chemotherapy
    Noppadol Larbcharoensub
    Department of Pathology, Faculty of Medicine at Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
    Hum Pathol 39:837-45. 2008
    ..041) and disease-free survival (P = .001). MRP1 expression can therefore be used as a potent molecular risk factor and a guide for chemotherapeutic regimens in patients with advanced stages of NPC...
  86. ncbi Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer
    Nicole J McCarthy
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20889, USA
    Clin Cancer Res 8:3857-62. 2002
    ..02; Bonferroni test). CONCLUSIONS: These data suggest that there is an increased MVD in breast cancer with the inflammatory phenotype as compared with breast cancer without the inflammatory phenotype...
  87. ncbi Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker
    G M Yousef
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada
    Cancer Res 61:7811-8. 2001
    ..We conclude that KLK9 is a potential new independent favorable prognostic marker for early stage, low-grade, optimally debulked ovarian cancer patients...
  88. ncbi p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis
    M J Pellikainen
    Department of Pathology and Forensic Medicine, University of Kuopio, FIN-70211 Kuopio, Finland
    J Clin Pathol 56:214-20. 2003
    ..001) and advanced stage (p < 0.001). CONCLUSIONS: The regulation of p21(WAF1) seems to occur independently of p53 or AP-2 and analysing p21(WAF1) expression provided no prognostic information for patients with breast cancer...
  89. ncbi Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer
    D Santini
    Department of Medical Oncology, University Campus Bio Medico, via Emilio Longoni 81, 00155 Rome, Italy
    Ann Oncol 19:724-8. 2008
    ....
  90. ncbi Roles of Fhit and p53 in Taiwanese surgically treated non-small-cell lung cancers
    Y L Chang
    Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, 100, Taiwan
    Br J Cancer 89:320-6. 2003
    ..001). Notably, p53 overexpression was associated with distant metastasis of patients in the whole series (P=0.027) and in adenocarcinoma (P=0.001). It was also associated with a poorer survival of patients with adenocarcinoma (P=0.032)...
  91. ncbi Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer
    Walter P Carney
    Oncogene Science, Bayer HealthCare, Cambridge, MA 02142, USA
    Clin Breast Cancer 5:105-16. 2004
    ....
  92. ncbi Expression and prognostic significance of 14-3-3sigma and ERM family protein expression in periampullary neoplasms
    Steven R Hustinx
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Cancer Biol Ther 4:596-601. 2005
    ..4; 0.9-2.2, p = 0.14). Aberrant expression of 14-3-3sigma may contribute to the outcome of patients with pancreatic ductal adenocarcinoma...
  93. ncbi Expression of IAP family proteins in colon cancers from patients with different age groups
    T Endo
    Department of Pathology and Immunology, Graduate School, Tokyo Medical and Dental University, 1 5 45 Yushima, Bunkyo ku, Tokyo 113 8519, Japan
    Cancer Immunol Immunother 53:770-6. 2004
    ..These results suggest that the expression of IAP family proteins, especially survivin, is associated with the age-related biological characteristics of colon cancer...
  94. ncbi Apoptosis in prostate cancer: bax correlation with stage
    Zahra Amirghofran
    Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran
    Int J Urol 12:340-5. 2005
    ..CONCLUSION: The patients in the present study showed a different pattern of apoptosis positivity compared to other reports. Bax expression may be a useful marker for prognosis of prostate cancer...
  95. ncbi Prognostic values of KAI1 and survivin expression in an infiltrating ductal carcinoma of the breast
    B H Son
    Department of General Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine [corrected] Seoul, Korea
    Pathology 37:131-6. 2005
    ..Four different groups, according to their survivin and KAI1 expression levels, correlated with the clinical stage and survival rate. CONCLUSION: KAI1 and survivin expression levels might be prognostic factors in breast cancers...
  96. ncbi Elevated cyclooxygenase-2 expression in patients with early gastric cancer in the gastric pylorus
    Hiroshi Yasuda
    Division of Gastroenterology, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Yokohama, 227-8501, Japan
    J Gastroenterol 40:690-7. 2005
    ..Bile acids induced COX-2 expression in human gastric cell lines, suggesting a role of bile reflux in gastric carcinogenesis...
  97. ncbi Significance of matrix metalloproteinase 9 and CD34 expressions in esophageal carcinoma: correlation with DNA content
    Ayman El Meghawry El-Kenawy
    Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute, Minufiya University, Sadat City, Minufiya, Egypt
    J Clin Gastroenterol 39:791-4. 2005
    ..The present study was carried out to evaluate the correlation between vascular endothelial cell marker (CD34), matrix metalloproteinase type 9 (MMP9), and DNA content in esophageal carcinoma...
  98. ncbi Loss of Fhit expression is associated with poorer survival in gastric cancer but is not an independent prognostic marker
    Emma Bragantini
    Dipartimento di Patologia, Sezione Anatomia Patologica, Universita di Verona, Strada Le Grazie, 8, 37134, Verona, Italy
    J Cancer Res Clin Oncol 132:45-50. 2006
    ..050). While loss of Fhit correlates with poorer survival in univariate analysis, it is not an independent prognostic factor in multivariate analysis and is thus not of clinical utility...
  99. ncbi Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers
    T Dutu
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 16:1906-14. 2005
    ..High levels of EGFR and Ki-67 are observed in smokers, while never-smokers are characterized by high levels of pAKT and p27...
  100. ncbi Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients
    Aya Nishizawa
    Pathology Division, National Cancer Center Research Institute, Tokyo, Japan
    Cancer 103:1693-700. 2005
    ..Recently, the authors reported a novel cell membrane glycoprotein, dysadherin, which has an anti-cell-cell adhesion function and down-regulates E-cadherin...
  101. ncbi Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer
    Daniel G Rosen
    Departments of Pathology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 11:632-7. 2005
    ....

Research Grants175 found, 100 shown here

  1. Early Biomarkers of Lung cancer by Gene Array Analysis
    Susan Boggs; Fiscal Year: 2003
    ..Expression profiling is expected to provide a new approach for comparisons between normal and cancerous cells, as well as to suggest potential targets for intervention. ..
  2. Protein Biomarkers of Cancer Risk in Older Persons
    Christopher Li; Fiscal Year: 2007
    ....
  3. Phase II Study of 44Gy from 131I-81C6 for CNS Tumors
    David Reardon; Fiscal Year: 2004
    ..To further define the toxicity of this approach and Specific Aim 3.To determine the impact of this therapy on quality of life. ..
  4. P21 INDUCTION BY BRCA2
    Fergus Couch; Fiscal Year: 2002
    ....
  5. Molecular signatures of HNSCC in response to targeted therapies
    Christine Chung; Fiscal Year: 2009
    ..Ultimately, we expect that the findings from this study will be translated into improved patient selection and optimized treatment benefits from EGFR inhibitors in HNSCC patients. ..
  6. Molecular signatures of HNSCC in response to targeted therapies
    Christine Chung; Fiscal Year: 2007
    ..Ultimately, we expect that the findings from this study will be translated into improved patient selection and optimized treatment benefits from EGFR inhibitors in HNSCC patients. ..
  7. Methodology of Phase I and II trials of anticancer CAM
    Andrew Vickers; Fiscal Year: 2004
    ....
  8. CLINICAL RESEARCH CURRICULUM
    David Ransohoff; Fiscal Year: 2004
    ..abstract_text> ..
  9. BRCA2 missense mutations and breast cancer
    Fergus Couch; Fiscal Year: 2009
    ..relevance of many missense mutations will have been determined and provided to the carriers who will then be able to benefit from improved cancer risk assessment, cancer prevention and perhaps even therapeutic strategies ..
  10. BRCA2 missense mutations and breast cancer
    Fergus Couch; Fiscal Year: 2007
    ..study the cancer relevance of many missense mutations will have been determined and provided to the carriers who will then be able to benefit from improved cancer risk assessment, cancer prevention and perhaps even therapeutic strategies ..
  11. BRCA2 missense mutations and breast cancer
    Fergus Couch; Fiscal Year: 2009
    ..study the cancer relevance of many missense mutations will have been determined and provided to the carriers who will then be able to benefit from improved cancer risk assessment, cancer prevention and perhaps even therapeutic strategies ..
  12. Genetic epidemiology of cell division regulation in breast cancer
    FERGUS JOSEPH COUCH; Fiscal Year: 2010
    ..The results will provide information for improved risk assessment and could provide targets for breast cancer prevention and therapeutic agents. ..
  13. Genetic epidemiology of cell division regulation in breast cancer
    Fergus Couch; Fiscal Year: 2009
    ..The results will provide information for improved risk assessment and could provide targets for breast cancer prevention and therapeutic agents. ..
  14. BRCA2 missense mutations and breast cancer
    FERGUS JOSEPH COUCH; Fiscal Year: 2010
    ..relevance of many missense mutations will have been determined and provided to the carriers who will then be able to benefit from improved cancer risk assessment, cancer prevention and perhaps even therapeutic strategies ..
  15. Colonoscopy Utilization in North Carolina
    David Ransohoff; Fiscal Year: 2006
    ..It may provide the basis to develop interventions to optimize the allocation of colonoscopy effort in programs of CRC screening and surveillance. ..
  16. Novel Methods for Integrative Analysis of Cancer Genomic Data
    Shuangge Ma; Fiscal Year: 2010
    ..Applications of the proposed methods will lead to identification of clinically useful cancer markers. ..
  17. Characterization of the Chromosome 17q23 Amplicon
    Fergus Couch; Fiscal Year: 2006
    ..Thus, the project may involve a complete transition from benchtop to bedside. Finally, the amplified and overexpressed genes may prove useful as important targets of gene, pharmacological, and immunological therapy in the future. ..
  18. A genome-wide association study for breast cancer in BRCA1 mutation carriers
    FERGUS JOSEPH COUCH; Fiscal Year: 2010
    ..The modifiers may also lead to development of improved risk assessment models that better discriminate between high and lower risk BRCA1 mutation carriers. ..
  19. CORI: Consortium Expansion and Database Enhancement
    David Lieberman; Fiscal Year: 2004
    ....
  20. Interaction of PTEN and CDKN1B in Pca susceptibility
    Jianfeng Xu; Fiscal Year: 2007
    ..The results from this study are likely to significant advance our knowledge of prostate cancer risk and begin to explore the underlying biological mechanisms for any observed differences. ..
  21. Clinical Outcomes Research: An Endoscopic Data Base
    David Lieberman; Fiscal Year: 2007
    ..Theme 4: Provide a resource to the scientific community. We have demonstrated successful collaboration with a wide range of clinical investigators to develop projects that are uniquely suited to a large community-based practice network. ..
  22. DNA Adducts of the Carcinogen Acetaldehyde
    Stephen Hecht; Fiscal Year: 2007
    ..These studies will provide critical data on the occurrence and biological significance of acetaldehyde DNA adducts and their possible role in human cancer. ..
  23. Telomere dysfunction, oxidative damage and breast cancer risk
    Jing Shen; Fiscal Year: 2007
    ....
  24. Oral Cancer, Chemoprevention, and Anti-Angiogenesis
    Mark Lingen; Fiscal Year: 2009
    ..abstract_text> ..
  25. Molecular physiology of mammalian INSP3 receptor
    J Kevin Foskett; Fiscal Year: 2009
    ..The results of these studies should provide new insights into the molecular physiology of this ubiquitous family of Ca2+ release channels. ..
  26. Cytosolic O-Glycosylation and Insulin Signaling
    Gerald Warren Hart; Fiscal Year: 2010
    ..Data from these experiments will reveal totally new avenues for developing treatments for diabetes. ..
  27. Phase III Trial of Exercise Training in Postsurgical Lung Cancer
    Lee Jones; Fiscal Year: 2009
    ..Despite its importance, effective interventions to improve exercise capacity among lung cancer patients are not available. ..
  28. Genetic Determinants of Lung Cancer Survival
    Ping Yang; Fiscal Year: 2010
    ..Our ultimate goal is to build comprehensive and clinically useful models in designing patient-specific treatment plans and in predicting patients'treatment response and survival. ..
  29. A Serum Marker for Aggressive Prostate Cancer
    Donna M Peehl; Fiscal Year: 2010
    ....
  30. Tamoxifen & Second Breast Cancer: Epidemiology/Pathology
    Christopher Li; Fiscal Year: 2007
    ..which women have increased or decreased risks of developing CBC if they use tamoxifen? (4) Among the CBC cases, how does tamoxifen alter the expression of these tumor markers in first compared to contralateral cancers? ..
  31. Molecular Profiling of Premalignant Oral Lesions
    Mark Lingen; Fiscal Year: 2007
    ..This molecular analysis may also greatly improve diagnostic prediction compared to the cellular pattern recognition currently used by pathologists. ..
  32. Advancing Child Health through Cellular and Molecular Biology
    Valerie Castle; Fiscal Year: 2007
    ....
  33. Depo-Provera and Breast Cancer: Epidemiology/Pathology
    Christopher Li; Fiscal Year: 2009
    ..such as parity and body mass index, modify this association?; and (3) Does the association between DMPA and breast cancer risk vary by histologic type or by the expression of steroid receptors including ERq, ERft, and PR? ..
  34. Risk Factors for Second Primary Breast Cancer Among DCIS Survivors
    Christopher I Li; Fiscal Year: 2010
    ....
  35. KALLIKREINS AS DIAGNOSTIC MARKERS OF OVARIAN CARCINOMA
    Eleftherios Diamandis; Fiscal Year: 2007
    ..Relevance of this research to public health: By achieving early ovarian cancer diagnosis, it will be possible to reduce the burden of the disease by administration of effective treatment as early as possible. ..
  36. c-erbB-2 and Risk of Contralateral Breast Cancer
    Christopher Li; Fiscal Year: 2007
    ....
  37. ER Reporter Genes To Predict Response To Endocrine Therapy
    WILLIAM SYMMANS; Fiscal Year: 2007
    ....
  38. A Serum Marker for Aggressive Prostate Cancer
    Donna Peehl; Fiscal Year: 2007
    ....
  39. Molecular Mechanisms in the Treatment of Neuroblastoma
    Valerie Castle; Fiscal Year: 2005
    ..abstract_text> ..
  40. Analysis to enhance sensitivity for membrane proteins
    Samir Hanash; Fiscal Year: 2002
    ....
  41. ORAL CANCER, RETINOIDS, AND ANTIANGIOGENESIS
    Mark Lingen; Fiscal Year: 2002
    ....